Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 46 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 1
19(41.3%)
Early Phase 1
17(37.0%)
N/A
8(17.4%)
Phase 2
2(4.3%)
46Total
Phase 1(19)
Early Phase 1(17)
N/A(8)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT07338604Early Phase 1Recruiting

Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Role: lead

NCT07312630Early Phase 1Recruiting

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Role: lead

NCT07284927Phase 1Recruiting

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

Role: lead

NCT07188610Phase 2Recruiting

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Role: lead

NCT06982534Early Phase 1Not Yet Recruiting

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Role: lead

NCT06982547Early Phase 1Not Yet Recruiting

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

Role: lead

NCT06092047Early Phase 1Recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Role: lead

NCT06970951Early Phase 1Not Yet Recruiting

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06871644Not ApplicableNot Yet Recruiting

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Role: lead

NCT06417398Early Phase 1Not Yet Recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06361745Not ApplicableRecruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06279026Not ApplicableRecruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Role: lead

NCT05562024Phase 1Recruiting

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Role: lead

NCT05731219Phase 1Unknown

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT05722171Early Phase 1Unknown

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT05170568Phase 1Unknown

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Role: lead

NCT05445011Phase 1Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Role: collaborator

NCT05432401Early Phase 1Unknown

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT05190185Phase 1Unknown

A Clinical Trial of TAA06 Injection in Advanced Solid Tumors

Role: lead

NCT05023707Phase 1Unknown

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator